Despite their "micro" size, microneedles involve manufacturing complexity and reliance on materials science that create far higher technical barriers than conventional hollow puncture needles. Minimally invasive surgical device manufacturers seeking to enter this field must deeply understand the paradigm shift in manufacturing-from "metal hollow needles" to "micron-scale array structures." This requires not just equipment upgrades, but a complete restructuring of knowledge systems.

The mainstream manufacturing pathways for microneedles are closely tied to their applications and determine distinct supply chain models:

Solid Microneedle Arrays: Primarily used to create microchannels in the skin and enhance drug or cosmetic penetration. Their manufacturing core lies in Micro-Electro-Mechanical Systems (MEMS) processes, especially deep reactive ion etching, or precision micro-injection molding. Common materials include silicon, metals (titanium, stainless steel), or medical-grade polymers. Manufacturers must master the technology of forming arrays with hundreds to thousands of needles of consistent shape, height, and tip curvature on a substrate of just a few square centimeters-an extreme test of nanometer-level mold precision and molding process control.

Dissolvable/Biodegradable Microneedle Arrays: A cutting-edge segment where needles are made of biomaterials like hyaluronic acid or PLGA (poly(lactic-co-glycolic acid)), encapsulating drugs that dissolve and release within the skin. Manufacturing relies on micromold technology, requiring expertise in biomaterial formulation rheology, post-forming drying processes (to prevent collapse and preserve drug activity), and long-term stability control. This demands close collaboration with biomaterial scientists and the development of end-to-end process know-how from material handling to final products.

Hollow Microneedles: Functionally closest to conventional injection needles, designed for direct liquid drug delivery. Their manufacturing represents the ultimate challenge in precision machining: drilling side or tip holes in ultra-fine tubing (outer diameter <200 microns) while ensuring unobstructed fluid flow. Key technologies include laser drilling and micro-electrical discharge machining (micro-EDM).

This technological diversity forces manufacturers to make strategic choices: specialize in one pathway (e.g., becoming a polymer microneedle injection molding expert) or build a multi-process platform? Regardless of the path, the following core capabilities form the foundation of competitive barriers:

Cross-Scale Precision Machining and Inspection: Investment in equipment such as electron beam lithography systems, laser direct-writing tools, and high-precision micro-injection molding machines, paired with scanning electron microscopes (SEM) and optical profilometers for nanometer-scale topography and dimensional verification.

Biomaterial Process Development: For dissolvable microneedles, establishing GMP-compliant production lines for biomaterial handling, mixing, filling, drying, and sterilization.

System Integration and Automated Assembly: Precision assembly of microneedle arrays with substrates, protective films, drug reservoirs, and other components. Achieving high-efficiency, high-yield automated assembly is critical for cost control.

Thus, competition in microneedle manufacturing is a comprehensive contest of precision engineering, biomaterials science, automation, and quality control. Traditional puncture needle manufacturers aiming to enter this space cannot rely solely on existing turning, milling, and grinding expertise. They must build core process databases and patent portfolios along new technological trajectories to evolve from simple "contract manufacturers" into solution providers with technological leadership.